{"id":1020638,"date":"2026-11-12T18:16:10","date_gmt":"2026-11-12T23:16:10","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/immucell-announces-unaudited-financial-results-for-the-quarter-ended-september-30-2026\/"},"modified":"2026-11-12T18:16:10","modified_gmt":"2026-11-12T23:16:10","slug":"immucell-announces-unaudited-financial-results-for-the-quarter-ended-september-30-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/immucell-announces-unaudited-financial-results-for-the-quarter-ended-september-30-2026\/","title":{"rendered":"ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2026"},"content":{"rendered":"
\n

PORTLAND, Maine, Nov. 12, 2026 (GLOBE NEWSWIRE) — ImmuCell Corporation (Nasdaq: ICCC) (\u201cImmuCell\u201d or the \u201cCompany\u201d), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today announced its unaudited financial results for the quarter ended September 30, 2026.<\/p>\n

\n
\n Management\u2019s Discussion:<\/u>
\n <\/strong>\n <\/p>\n

\u201cToday we are reporting net income of $953,000 for the third quarter of 2026, a $1.1 million increase compared to the third quarter of 2025,\u201d commented Timothy C. Fiori, Chief Financial Officer of ImmuCell. \u201cRevenue grew 46.0% to $8.0 million in the third quarter of 2026 compared to the third quarter of 2025, a comparison aided in part by the absence of distributor restocking headwinds that had adversely affected the third quarter sales in 2025. Gross margin was 44.2% in the third quarter of 2026, which is 130 basis points higher than the third quarter of 2025 and reflects higher pricing and manufacturing execution partially offset by the previously discussed shift of certain product development expenses to costs of goods sold.\u201d<\/p>\n

\u201cWe are pleased with our third quarter revenue and with distributor out-the-door volume growth of 18% over 2025,\u201d commented Bobbi Jo Brockmann, Senior Vice President of Sales & Marketing. \u201cGrowth remained broad-based across our sales territories and product lines, supported by an increase in sales activity and continued progress in customer acquisition. We are also encouraged by inventory levels heading into our peak season as we shift our focus to the cow-calf market.\u201d<\/p>\n

\u201cImmuCell had a strong quarter. The expanded commercial team is delivering solid revenue growth as we reach more customers with our value propositions,\u201d said Olivier te Boekhorst, President and CEO. \u201cIncreased commercial activity was supported by increased output from the manufacturing team. We are investing in capacity expansion and colostrum sourcing capabilities for future demand, and those efforts are projected to be completed on time and within budget.\u201d<\/p>\n

\u201cWe have negotiated a new, larger $3 million line of credit with our bank, which we expect to sign during the fourth quarter of 2026,\u201d continued Mr. Fiori. \u201cAdditionally, given our strong cash position, we have terminated our At-The-Market offering.\u201d<\/p>\n

\n
\n Certain Financial Results:<\/u>
\n <\/strong>\n <\/p>\n